Every 10-Q that Immix Biopharma Inc (IMMX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMMX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMMX filings page.
Immix Biopharma, a clinical-stage cell therapy company focused on CAR-T candidate NXC-201, reported a net loss of $11.6 million for the quarter ended June 30, 2026, compared with $6.6 million a year earlier. Operating expenses were $12.5 million, including general and administrative expenses of $7.1 million and research and development costs of $5.3 million. Interest income rose to $0.9 million, reflecting larger cash and investment balances.
For the first half of 2026, net loss was $21.6 million versus $11.2 million in the prior-year period, on total operating expenses of $23.3 million. Loss per share was $0.36, compared with $0.37, as the weighted-average share count increased to 59.6 million from 29.8 million.
As of June 30, 2026, cash, cash equivalents and short-term investments totaled approximately $232.1 million, plus $2.1 million of long-term U.S. Treasury investments. This position reflects a May 2026 underwritten offering that generated approximately $140.7 million in net proceeds and sales under a $100 million at-the-market program. Total liabilities were $10.2 million and stockholders’ equity was $228.9 million. The company believes its existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements for at least the next 12 months as it advances the Phase 1b/2 NEXICART-2 trial and other development activities, supported in part by an $8.0 million CIRM grant.
Immix Biopharma, Inc. reported a larger net loss as it continues to invest heavily in its cell therapy pipeline. For the three months ended March 31, 2026, net loss was $10.1 million, compared with $4.5 million a year earlier, driven by higher research and development and general and administrative expenses totaling $10.8 million.
Cash, cash equivalents and short-term investments were $90.6 million as of March 31, 2026, and total stockholders’ equity was $84.4 million. The company states this liquidity should fund operating and capital needs for at least 12 months from the filing of the quarterly report while it advances NXC‑201 and other programs.
Immix Biopharma reported third-quarter 2025 results, highlighting continued R&D investment and financing activity alongside a going concern warning. The company posted a net loss of $7,585,692 for Q3 and $18,750,783 for the nine months ended September 30, 2025. Operating expenses were $7,662,509 in Q3, driven by R&D $4,584,131 and G&A $3,078,378.
Liquidity remained constrained with cash and cash equivalents of $15,947,308 at quarter-end and operating cash use of $12,900,697 year-to-date. Management stated there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months.
To fund operations, Immix raised capital via a private placement of 3,915,604 shares and 2,936,709 warrants at a combined price of $2.37, yielding ~$9.3 million gross, and through an ATM program that delivered net proceeds of $2,573,375 for the nine months. The CIRM grant award totals $8 million, with ~$4.6 million received to date and ~$3.4 million remaining subject to milestones. Shares outstanding were 33,577,873 as of November 5, 2025.
Immix Biopharma, Inc. reported cash and cash equivalents of $11.6 million at June 30, 2025, down from $17.7 million at year-end, total assets of $15.6 million and total stockholders' equity of $4.65 million. The company recorded a $11.17 million net loss for the six months and operating expenses of $11.4 million over the same period, reflecting continued R&D and G&A spending. Management states it does not have sufficient capital to sustain operations through the next twelve months and discloses substantial doubt about the company’s ability to continue as a going concern.
On the financing and development side, Immix established a $50 million ATM facility and sold 513,935 shares for net proceeds of $1.09 million during the quarter (1,015,347 shares sold for $2.43 million as of August 6, 2025). Clinically, lead candidate NXC-201 has favorable early results: prior cohorts showed overall response rates of 100% (10/10) and 94% (15/16) with complete response rates of 70–75%, and the program holds FDA RMAT and orphan drug designations and an $8 million CIRM grant with $3.6 million received to date.